Loading...
Loading...
India's amiodarone imports from AUSTRALIA total $2.9K across 1 shipments from 1 foreign suppliers. PHARMAQUELLE LLC leads with $2.9K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include INDOCO REMEDIES LIMITED. This corridor reflects India's pharmaceutical import demand for amiodarone โ a concentrated sourcing relationship with select suppliers from AUSTRALIA.

PHARMAQUELLE LLC is the leading Amiodarone supplier from AUSTRALIA to India, with import value of $2.9K across 1 shipments. The top 5 suppliers โ PHARMAQUELLE LLC โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | PHARMAQUELLE LLC | $2.9K | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | INDOCO REMEDIES LIMITED | $2.9K | 1 | 100.0% |
AUSTRALIA โ India trade corridor intelligence
The Australia to India trade corridor for pharmaceutical imports is currently stable. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion. Freight rates have remained consistent over the past year, and the exchange rate between the Indian Rupee (INR) and Australian Dollar is favorable for importers. No significant disruptions have been reported in the supply chain during 2025โ2026.
The implementation of the Production Linked Incentive (PLI) scheme has impacted the import of finished pharmaceutical formulations from Australia. The scheme aims to boost domestic manufacturing and reduce import dependency. However, the demand for specialized formulations not available domestically continues to drive imports from Australia. Import substitution policies are being evaluated to balance the need for self-reliance with the requirement for high-quality imported medicines.
The trade relationship between India and Australia has strengthened, with ongoing Free Trade Agreement (FTA) negotiations focusing on mutual recognition of Good Manufacturing Practices (GMP) and pharmaceutical trade facilitation. These efforts aim to streamline the import process, reduce regulatory barriers, and enhance the availability of quality pharmaceutical products in the Indian market.
The landed cost of importing finished Amiodarone formulations from Australia to India includes the following components:
Per-unit estimates can be calculated by summing these components and dividing by the number of units imported.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Amiodarone into India, the Central Drugs Standard Control Organization (CDSCO) mandates that the importer obtain an Import Registration Certificate and an Import License as per the Drugs and Cosmetics Act and Rules. The registration process involves submitting Form 40 or 41 to CDSCO, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for import drug registration can vary, but it typically takes several months to complete. For formulations under HS Code 30049099, the importer must ensure compliance with all regulatory requirements, including obtaining a No Objection Certificate (NOC) from CDSCO, if applicable.
Imported finished pharmaceutical formulations containing Amiodarone are subject to quality testing by CDSCO-approved laboratories. Each batch must be accompanied by a Certificate of Analysis (CoA) and stability data demonstrating compliance with International Council for Harmonisation (ICH) Zone IV standards. The formulations must meet the standards specified in the Indian Pharmacopoeia. Upon arrival at Indian ports, customs drug inspectors conduct inspections to verify the authenticity and quality of the imported products. Any discrepancies or failures in quality testing can lead to delays, rejections, or destruction of the goods.
In April 2025, the Indian government introduced new regulations requiring import registration and licenses for all imported medicines, including finished pharmaceutical formulations containing Amiodarone. This measure aims to prevent the sale of unapproved or illegal medicines in the Indian market. The implementation of the Production Linked Incentive (PLI) scheme has also impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports. Bilateral agreements between India and Australia have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), thereby streamlining the import process for Australian pharmaceutical products.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Amiodarone formulations to meet the demand for patented or branded products, specific dosage forms, and formulations not available domestically. The domestic capacity for manufacturing Amiodarone formulations is limited, leading to a reliance on imports to fulfill market needs. The market size for Amiodarone formulations in India is substantial, with a significant volume of imports to cater to the therapeutic requirements of patients.
The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. The Social Welfare Surcharge (SWS) is 10% of the BCD, resulting in an additional 1% duty. The Integrated Goods and Services Tax (IGST) is applicable as per prevailing rates, which can vary. There are no specific exemptions or concessional duty rates for Australian-origin products under this HS code. The total landed duty percentage combines these components, affecting the final cost of imported goods.
India sources finished Amiodarone formulations from Australia due to the availability of patented formulations, specialized dosage forms, and high-quality products. Australian manufacturers adhere to stringent quality standards, ensuring the safety and efficacy of their products. While other suppliers like China, Germany, and the United States also export Amiodarone formulations to India, Australia's share remains significant due to its competitive advantages in quality and regulatory compliance.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Amiodarone formulations from Australia due to the availability of patented formulations, specialized dosage forms, and high-quality products. Australian manufacturers adhere to stringent quality standards, ensuring the safety and efficacy of their products. These formulations are often not available domestically, making imports essential to meet the therapeutic needs of patients.
When compared to other origins like China, the European Union, and the United States, Australia offers competitive advantages in terms of product quality, regulatory compliance, and reliability. Australian pharmaceutical products are known for their adherence to international standards, which is crucial for the Indian market. While other countries may offer lower prices, Australia's consistent quality and compliance with regulatory requirements make it a preferred source for importing Amiodarone formulations.
Indian importers face several supply chain risks when sourcing finished Amiodarone formulations from Australia, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, monitoring currency exchange rates, staying updated on regulatory changes, and establishing contingency plans for potential disruptions.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Amiodarone suppliers from AUSTRALIA to India include PHARMAQUELLE LLC. The leading supplier is PHARMAQUELLE LLC with import value of $2.9K USD across 1 shipments. India imported Amiodarone worth $2.9K USD from AUSTRALIA in total across 1 shipments.
India imported Amiodarone worth $2.9K USD from AUSTRALIA across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Amiodarone sourced from AUSTRALIA include INDOCO REMEDIES LIMITED. The largest buyer is INDOCO REMEDIES LIMITED with $2.9K in imports across 1 shipments.
The total value of Amiodarone imports from AUSTRALIA to India is $2.9K USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists